By: IPP Bureau
Last updated : December 01, 2025 10:27 am
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Sun Pharmaceutical Industries launches its global innovative drug, Ilumya (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, Ilumya has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.
"Ilumya offers a safe and effective treatment option for patients who are struggling to manage their moderate-tosevere plaque psoriasis," said Kirti Ganorkar, Managing Director, Sun Pharma.
"We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years."
Sun Pharma's clinical study in India included 115 patients of moderate-to-severe plaque psoriasis. Significant improvements were also observed on additional efficacy endpoints such as, Dermatology Life Quality Index (DLQI) score. a.
"Having been involved in the clinical development of Tildrakizumab in India, I am pleased to see its potential as an effective, safe, and long-lasting treatment for psoriasis. In the Phase-3 trial, tildrakizumab demonstrated significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance." said Dr. B. S. Chandrashekar, Chief Dermatologist and Managing Director at Cutis Academy of Cutaneous Sciences, Bengaluru, India who was also an investigator in India Phase 3 trial. "These results showcase its benefits in improving the quality of life for psoriasis patients."
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that Ilumya is a sustainable choice for patients over the long term.